Sign in
Download Opera News App

DISEASE PREVENTION AND TREATMENT

ObsEva Submits NDA Of Linzagolix To FDA For Treatment Of Uterine Fibroids

ObsEva Submits NDA Of Linzagolix To FDA For Treatment Of Uterine Fibroids

ObsEva SA (OBSV) said Wednesday that it has submitted a New Drug Application to the U.S. Food and Drug Administration for linzagolix for the treatment of uterine fibroids. Linzagolix is an oral GnRH receptor antagonist with potential best-in-class efficacy, favorable tolerability profile, and unique and flexible dosing options. Further, if approved,...

Read Full Story
GnRH Linzagolix NDA OBSV ObsEva linzagolix

Top News

US POLITICS

Newsom: Presidential bid has '100 percent never been on my radar'

thehill.com
Newsom: Presidential bid has '100 percent never been on my radar'

US POLITICS

Newsom: Presidential bid has '100 percent never been on my radar'

thehill.com

GOSSIP CELEBRITY

See singer and actor Nick Jonas through the years

usatoday.com
See singer and actor Nick Jonas through the years

GOSSIP CELEBRITY

See singer and actor Nick Jonas through the years

usatoday.com

comments

Load app to read more comments